Ali Habib, MD
Neuromuscular Medicine · Orange, CANPI 1518124288
Payments from drug & device makers
Across 595 payments — averaging $2721.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$291K
- AstraZeneca$271K
- Argenx US, Inc.$229K
- Regeneron$171K
- Amgen$154K
- Novartis$116K
- plus $387K from 26 others
Across 15 payments — averaging $1078.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB, Inc.$11K
- F. Hoffmann-la Roche AG$2K
- AstraZeneca$2K
- Regeneron$819
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 56 | $291,419 |
| AstraZeneca(2 entities) | 127 | $270,877 |
| Argenx US, Inc. | 116 | $229,333 |
| Regeneron | 62 | $171,318 |
| Amgen(2 entities) | 29 | $154,424 |
| Novartis | 8 | $115,546 |
| Genentech, Inc. | 27 | $114,897 |
| UCB, Inc. | 66 | $84,474 |
| Ares Trading SA | 12 | $42,552 |
| Chugai Pharmaceutical Co., Ltd. | 3 | $42,132 |
| Johnson & Johnson(2 entities) | 18 | $22,203 |
| Sanofi | 3 | $21,896 |
| UCB Biosciences Inc. | 5 | $20,500 |
| F. Hoffmann-la Roche AG | 6 | $11,596 |
| Grifols USA, LLC | 20 | $5,004 |
| Catalyst Pharmaceuticals, Inc. | 4 | $4,675 |
| Janssen Scientific Affairs, LLC | 3 | $3,638 |
| Grifols Shared Services North America, Inc. | 6 | $2,524 |
| Pfizer | 1 | $2,500 |
| Merck Kgaa | 2 | $2,193 |
| GC Biopharma USA, Inc. | 1 | $2,000 |
| Amylyx Pharmaceuticals, Inc. | 1 | $1,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,360 |
| CSL Behring | 5 | $249 |
| Roche Products Limited | 2 | $245 |
| Sarepta Therapeutics, Inc. | 3 | $153 |
| Biogen | 1 | $121 |
| Octapharma USA, Inc. | 2 | $84 |
| Tanabe Pharma America, Inc. | 1 | $33 |
| EMD Serono Research & Development Institute, Inc. | 1 | $27 |
| EDW Pharma, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 2 | $2 |
How this compares
$1,619,493 in reported general payments places this provider in the 95th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neuromuscular medicine in Orange
- Tahseen MozaffarOrange$3.2M
- Namita GoyalOrange$1.5M
- Jeffrey MullenOrange$169K
- Jay HanOrange$126K
- Khalid AlrasheedOrange$75K
- Jonathan CauchiOrange$895
- Mona Rezaei MirghaedOrange$673
- John DayStanford$14.4M
- Jeffrey RosenfeldFresno$1.5M
- Samir MacwanRancho Mirage$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.